EPLBA01 Protective potential of non-neutralizing mAbs targeting immunodominant Env epitopes against tier-2 HIV-1E-posterHumoral immunity (including broadly neutralizing antibodies), Antibodies and B cells
EPLBA02 Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T cell correlates of HIV-1 acquisition riskE-posterCellular immunity; T cell vaccines
EPLBA03 Transcriptome analysis to identify the changes in microRNA expression profile and their targeted pathways in the cervicovaginal mucosa of HIV-infected womenE-posterMucosal immunity
EPLBA04 CD8 depletion and N-803 plus anti-SIV Env RhmAbs in ART-suppressed rhesus macaquesE-posterStrategies to control virologic rebound
EPLBA05 Translational potency of the antisense protein ORF in the proviral DNA contextE-posterHIV biology (entry, replicative cycle, transcriptional expression and regulation)
EPLBA06 Deep down in the gut: analyzing the connection between epithelial cells and ART-induced inflammationE-posterHIV and co-morbidities
EPLBA07 Host genetic variants regulates CCR5 expression on immune cells: a study in people living with HIV and healthy controlsE-posterCorrelates of HIV susceptibility, and progression versus control (biomarkers and genetics)
EPLBA08 ILC3s in HIV-infected lymph nodes up-regulate inflammatory pathways linked to tissue fibrosisE-posterInnate immunity (including NK cells)
EPLBB01 Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomized controlled trialE-posterTuberculosis: Prevention, diagnosis, treatment
EPLBB02 Chronic/latent viral infection prevalence and estimated all-cause mortality risk among women living with HIV and HIV-negative women participating in the British Columbia CARMA-CHIWOS Collaboration (BCC3) study: preliminary findingsE-posterOpportunistic infections (excluding TB): Bacterial, non-TB mycobacterial, viral and parasitic infections
2431 - 2440 of 2485 items